Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Clinical trial NCT06982521 · RECRUITING

Trial details

NCT number: NCT06982521
Sponsor: Relay Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

PIK3CA Mutation HER2- Negative Breast Cancer Hormone Receptor Positive Tumor Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer

Start date: 2025-08-26
Primary completion: 2028-04-30
Enrollment: 540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.